Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
National Cancer Institute (NCI)
National Cancer Institute (NCI)
AstraZeneca
Merck Sharp & Dohme LLC
Eli Lilly and Company
Verastem, Inc.
National Cancer Institute (NCI)
Bayer
Hoffmann-La Roche
National Institutes of Health Clinical Center (CC)
Seagen Inc.
Seagen Inc.
Seagen Inc.
Hoffmann-La Roche
Amgen
Eli Lilly and Company
Pliant Therapeutics, Inc.
Pfizer
Eli Lilly and Company
Merck Sharp & Dohme LLC
Pfizer
Eli Lilly and Company
Merck Sharp & Dohme LLC
Pfizer
Merck Sharp & Dohme LLC
Compass Therapeutics
McGill University Health Centre/Research Institute of the McGill University Health Centre
SWOG Cancer Research Network
Merck Sharp & Dohme LLC
M.D. Anderson Cancer Center
InSightec
Merck Sharp & Dohme LLC
University of Pittsburgh
ImmunityBio, Inc.
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Exelixis
BioNTech SE
Bristol-Myers Squibb
Astellas Pharma Inc
Merck Sharp & Dohme LLC
Amgen
Merck Sharp & Dohme LLC
Hoffmann-La Roche
EMD Serono
Bristol-Myers Squibb
ImmunityBio, Inc.
The Methodist Hospital Research Institute
Genmab
Big Ten Cancer Research Consortium
IO Biotech
Merck Sharp & Dohme LLC